1. Immunomodulating therapy with rIL-2 and interferon alpha-induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study).
- Author
-
Demir G, Ozguroglu M, Sayhan N, Molinas-Mandel N, Demirelli F, Buyukunal E, Tuzuner N, Serdengecti S, and Berkarda B
- Subjects
- Adult, Aged, Bone Neoplasms secondary, Carcinoma, Renal Cell drug therapy, Fas Ligand Protein, Female, HLA-DR Antigens biosynthesis, Humans, Kidney Neoplasms drug therapy, Liver Neoplasms secondary, Lung Neoplasms secondary, Lymphocytes drug effects, Male, Middle Aged, Pilot Projects, Prospective Studies, Receptors, Interleukin-2 biosynthesis, Time Factors, Adjuvants, Immunologic therapeutic use, Interferon-alpha therapeutic use, Interleukin-2 therapeutic use, Lymphocytes metabolism, Membrane Glycoproteins biosynthesis, Proto-Oncogene Proteins c-bcl-2 biosynthesis, Recombinant Proteins therapeutic use, fas Receptor biosynthesis
- Abstract
The first Phase I Trial with a combination of IL-2 and IFN-alpha was published in 1989. There are still some questions though, concerning the in vivo effects of this combination on lymphocytes. We designed a prospective pilot study to evaluate in vivo effects of low dose IL-2 and IFN-alpha combination on expression of Bcl-2, FAS (Apo-1/CD 95), Fas Ligand, IL-2 receptor (CD25), and HLA-DR on peripheral lymphocytes in patients with advanced renal cell carcinoma. After initiation of the immunomodulating therapy, Bcl-2 expressing lymphocytes increased significantly on day 3 (p < 0.025), Fas (Apo-1/CD95) expressing lymphocyte increased significantly on day 5 (p < 0.003), Fas ligand expressing lymphocytes increased significantly on day 3 (p < 0.004), HLA-DR expressing lymphocytes increased significantly on day 5 (p < 0.003), and IL-2 receptor (CD25) expressing cells increased significantly on day 5 (p < 0.01). We conclude that immunomodulating therapy induces in vivo expression of Bcl-2, Fas (Apo-1) and Fas Ligand in lymphocytes significantly.
- Published
- 1999